Medicare Advantage · SOP con síndrome metabólico · Versión completa en inglés: /pa-letter/medicare-advantage--pcos/
Carta de PA para Medicare Advantage: SOP con síndrome metabólico.
Plantilla defensible de carta para Wegovy, Zepbound or off-label Mounjaro depending on T2D status. PCOS is not an FDA-approved indication for GLP-1, but PCOS with documented insulin resistance, prediabetes or obesity qualifies under the obesity or T2D pathways.
La carta misma está en inglés porque el revisor del plan la lee en inglés. La envuelve y la firma su clínico.
Cita de política: Plan-specific Medicare Advantage formulary and PA criteria.
Nota del plan: Medicare does not cover GLP-1 for obesity indication under federal statute (the 2003 MMA exclusion). For patients with documented type 2 diabetes, Medicare Advantage plans cover Ozempic and Mounjaro under the T2D indication. For patients with established cardiovascular disease and obesity or overweight, Medicare Advantage plans may cover Wegovy under the SELECT FDA-labeled cardiovascular indication (approved March 2024). For patients with moderate-to-severe obstructive sleep apnea and obesity, Medicare Advantage plans may cover Zepbound under the SURMOUNT-OSA FDA-labeled OSA indication (approved December 2024). The CV and OSA pathways follow FDA labeling and are evaluated against the plan's medical-necessity criteria for each indication.
Nota del plan: Medicare does not cover GLP-1 for obesity indication under federal statute (the 2003 MMA exclusion). For patients with documented type 2 diabetes, Medicare Advantage plans cover Ozempic and Mounjaro under the T2D indication. For patients with established cardiovascular disease and obesity or overweight, Medicare Advantage plans may cover Wegovy under the SELECT FDA-labeled cardiovascular indication (approved March 2024). For patients with moderate-to-severe obstructive sleep apnea and obesity, Medicare Advantage plans may cover Zepbound under the SURMOUNT-OSA FDA-labeled OSA indication (approved December 2024). The CV and OSA pathways follow FDA labeling and are evaluated against the plan's medical-necessity criteria for each indication.
Lo que OptumRx realmente requiere
Medicare Advantage contrata la administración del beneficio de farmacia a OptumRx, que adjudica esta PA. Los criterios siguientes provienen de la política clínica del PBM publicada públicamente. Cumpla cada uno antes de enviar.
- BMI greater than or equal to 30 with one comorbidity, OR BMI greater than or equal to 35 alone (post-2025 tightening)
- Six months of documented dietary intervention with structured weight-management program participation
- Step therapy through phentermine OR orlistat
- 6-month reauthorization checkpoint requiring documented weight loss greater than or equal to 4 percent from baseline
- Some employer carve-outs exclude obesity-indication GLP-1 entirely; check plan's specific formulary
La carta (copiar y editar)
Copie el cuerpo a continuación y péguelo en el portal de su clínico o procesador de textos. Reemplace cada marcador de posición entre [CORCHETES] con datos específicos del paciente antes de enviar. La carta es de su clínico al plan, firmada por su clínico.
[Today's date] Medicare Advantage (generic letter) Prior Authorization Department Submitted via: Plan-specific portal or CoverMyMeds Re: Prior Authorization Request, Wegovy, Zepbound or off-label Mounjaro depending on T2D status Patient: [Patient full name] Member ID: [Plan member ID] Date of birth: [Patient DOB] Group number: [Group number if applicable] Prescriber: [Prescriber full name, NPI, DEA] Prescriber contact: [Phone, fax, email] To the Medicare Advantage (generic letter) Prior Authorization Reviewer, I am the treating clinician for [Patient name]. I am writing to request prior authorization for Wegovy, Zepbound or off-label Mounjaro depending on T2D status for treatment of PCOS with metabolic syndrome (ICD-10: E28.2, E66.9, R73.03). Clinical justification PCOS itself is not an FDA-approved indication for any GLP-1 receptor agonist, but PCOS frequently coexists with insulin resistance, prediabetes and obesity, each of which is a qualifying indication. This PA pathway requests coverage under the obesity indication (if BMI greater than or equal to 30 or 27 with comorbidity) or under the T2D indication (if A1c greater than or equal to 6.5 percent). PCOS-specific evidence: a 2023 systematic review in Reproductive Sciences pooled GLP-1 trial data in women with PCOS and found significant improvements in BMI, insulin resistance (HOMA-IR) and androgen levels at 12 to 24 weeks of treatment. Patient-specific findings - [Insert current measurements: weight, height, BMI, blood pressure] - [Insert relevant lab values with dates: A1c, lipid panel, kidney function] - [Insert documentation of comorbidities with ICD-10] - [Insert documentation of prior treatment history, including any prior GLP-1 trials, anti-obesity medication trials or lifestyle intervention] Criteria met per Medicare Advantage (generic letter) policy This request meets the criteria set out in Plan-specific Medicare Advantage formulary and PA criteria: - PCOS diagnosis documented with ICD-10 E28.2 (often confirmed by Rotterdam criteria) - Documentation of metabolic complications: insulin resistance, prediabetes (A1c 5.7 to 6.4) or T2D (A1c greater than or equal to 6.5) - BMI documented (qualifies under obesity pathway if 30 or above, or 27 with comorbidity) - Six-month lifestyle intervention documented for the obesity pathway - Endocrinology or reproductive endocrinology consult letter (strengthens but not always required) Supporting evidence The clinical case for Wegovy, Zepbound or off-label Mounjaro depending on T2D status in this indication is supported by the following registration trials and outcomes data: - Jensterle et al. 2014 (liraglutide in PCOS, Endocrine Connections) - Frossing et al. 2018 (liraglutide in PCOS, Diabetes Obesity and Metabolism) - Pooled meta-analyses of GLP-1 in PCOS (Reproductive Sciences 2023) Plan-specific note Medicare does not cover GLP-1 for obesity indication under federal statute (the 2003 MMA exclusion). For patients with documented type 2 diabetes, Medicare Advantage plans cover Ozempic and Mounjaro under the T2D indication. For patients with established cardiovascular disease and obesity or overweight, Medicare Advantage plans may cover Wegovy under the SELECT FDA-labeled cardiovascular indication (approved March 2024). For patients with moderate-to-severe obstructive sleep apnea and obesity, Medicare Advantage plans may cover Zepbound under the SURMOUNT-OSA FDA-labeled OSA indication (approved December 2024). The CV and OSA pathways follow FDA labeling and are evaluated against the plan's medical-necessity criteria for each indication. Requested action I am requesting prior authorization for Wegovy, Zepbound or off-label Mounjaro depending on T2D status at the [insert starting dose] starting dose, with planned titration per FDA labeling. I am also requesting that this authorization be granted for a continuous 12-month period subject to documented clinical response, per standard formulary practice. If additional information is required, please contact me directly at [Prescriber phone] or [Prescriber email]. I am available to discuss this case with your medical director if helpful. Thank you for your attention to this request. Sincerely, [Prescriber full signature] [Prescriber printed name, credentials] [Prescriber NPI] [Practice name and address] Attachments: - Current vital signs and BMI calculation - Most recent relevant labs - Documentation of comorbidities - Documentation of prior treatment trials - Sleep study report (if OSA indication) - Cardiac history documentation (if CV indication)
Aviso legal
Plantillas educativas únicamente. No constituyen asesoramiento legal ni médico. Las cartas deben ser firmadas por el clínico tratante (MD, DO, NP, PA) con autoridad de prescripción. Cada plan cambia los criterios trimestralmente. Verifique con el boletín de política de PA más reciente de su plan antes de enviar. No invente hallazgos clínicos. No altere la firma de un clínico.
Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. No removal of unfavorable information at advertiser request. Pricing is pulled from each program's public-facing page weekly.